2993 results about "Cancer" patented technology

Compounds of Formulae (I)-(VII) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formulae (I)-(VII) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a RTK-MAPK pathway inhibitor and a compound of Formula (I).

Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of an immunomodulator inhibitor and a compound of Formula (I).

Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a Q61H, G12D, G12V, G12C, G12S, G12A, G12R, or G13D mutation or wild-type KRAS, including wild-type amplified KRAS) and treating diseases or disorders such as cancers in subjects in need thereof.

The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.

The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

The present invention relates to a compound as shown in formula (A) having a pan-RAS inhibitory effect, or an isotopic derivative or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound, and the use of the compound of formula (A) in the prevention and / or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.

The invention relates to the technical field of assessment and early warning systems, and particularly discloses a rectal cancer operation risk assessment and early warning system based on multi-modal data fusion, which comprises a multi-modal data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic risk assessment module, an intelligent early warning module and a system self-checking module. By integrating multi-modal data and dynamically allocating weights, real-time risk updating in the whole operation period is achieved, the comprehensiveness, timeliness and precision of risk assessment are comprehensively improved by combining the grading early warning function, the autonomous detection calibration function and the risk tracing and countermeasure matching function, long-term reliable operation of the system is guaranteed, powerful support is provided for clinical decision making, and the risk assessment method is suitable for clinical decision making. The surgical risk and the complication occurrence rate are effectively reduced.

This document generally describes methods and systems for generating digital reconstructions of tissue from humans or other species. The method can, for example, include receiving, at a computing system, image data of a tissue sample, where one or more sections of the tissue sample are stained with hematoxylin and eosin (H&E), registering the image data to generate registered image data, identifying tissue subtypes based on application of a machine learning model to the registered image data, annotating the identified tissue subtypes to generate annotated image data, and determining a digital volume of the tissue sample in three dimensional (3D) space based on the annotated image data. The disclosed technology can provide for single-cell analysis and other analysis of tissue samples, such as early detection of cancer in human tissue samples.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

Provided are a compound represented by formula (I) and a pharmaceutical composition comprising the compound, and a use of a compound of formula (A) for preventing and / or treating cancer, tumor, inflammatory disease, autoimmune disease, or immune-mediated disease.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

In the disclosed systems and methods for characterizing a cancer condition of a tissue in a subject, a computer system inputs information into an ensemble model. The information includes, for each respective class of radiomics features in a plurality of classes of radiomics features, a corresponding value for each respective radiomic feature in a corresponding plurality of radiomics features of the respective class of radiomics features obtained from a medical imaging dataset. The ensemble model comprises a plurality of component models. The computer system obtains as output from each respective component model in the plurality of component models a corresponding component prediction for the cancer condition, thereby obtaining a plurality of component predictions for the cancer condition. The computer system combines the plurality of component predictions to obtain as output of the ensemble model a characterization of the cancer condition.

The invention relates to an HPV16 type E6 oncoprotein monoclonal antibody as well as a preparation method and application thereof. The monoclonal antibody specifically bound with the HPV16E6 recombinant antigen is obtained through screening, the monoclonal antibody is applied to a biotin-avidin amplification ELISA system, the E6 oncoprotein of HPV16 can be specifically detected, the sensitivity is 100 pg / mL, the monoclonal antibody does not intersect with oncoprotein of other high-risk HPV, and the E6 oncoprotein of HPV16 can be specifically detected. High specificity and sensitivity are shown for cervical exfoliated cell sample detection of normal people, CIN3 people and cervical cancer people, and the method can be applied to early screening of cervical cancer in the future; compared with traditional exfoliative cytology examination, the method is faster and more accurate, meanwhile, the risk of false positive and misdiagnosis caused by too high sensitivity of nucleic acid detection can be avoided, and the method has very high application value.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and / or hydrate, and / or cocrystal, and / or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and / or symptoms and / or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Detecting cross-contamination between test samples used for determining cancer in a subject is beneficial. To detect cross-contamination, test sequences including at least one single nucleotide polymorphism are prepared using genome sequencing techniques. Some of the test sequences can be filtered to improve accuracy and precision. A prior contamination probability for each test sequence is determined based on a minor allele frequency. A contamination model including a likelihood test is applied to a test sequence. The likelihood test obtains a current contamination probability representing the likelihood that the test sample is contaminated. The contamination model can also determine a likelihood that the sample includes loss of heterozygosity representing the likelihood that the test sequence is contaminated. Test samples that are contaminated are removed. A source for the contaminated test sample can be found by comparing contaminated test sequences to other test sequences.

This disclosure relates to homodimeric antibodies for use in treating cancer generally and to both homodimeric antibodies that bind human sperm protein 17 (Sp17) and homodimeric antibody immunoconjugates specifically. Such homodimeric antibodies display improved properties relative to monomeric antibodies, for example, because they can crosslink cells, improve cellular uptake, and / or carry greater payloads.

The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.

Disclosed are approaches to data acquisition, analysis, and computational forecasting that employs quantitative MRI data to predict the response of cancer to therapy. Example protocols detail how to acquire needed images followed by registration, segmentation, quantitative perfusion and diffusion analysis, model calibration, and prediction. The response of individual cancer patients to therapy is forecast by application of a biophysical, reaction-diffusion model to these data. Application of the protocol results in coregistered MRI data from at least two scan visits that quantifies an individual tumor's size, cellularity and vascular properties. This enables a spatially resolved prediction of how a particular patient's tumor will respond to therapy. A modified therapy can be determined based on predicted response.

The invention relates to the technical field of CT (Computed Tomography) image analysis and labeling, in particular to a method for finely labeling colon cancer lesions in CT images. The method comprises the following steps: firstly, acquiring an intestinal wall section corresponding to each non-intestinal wall section area in an intestinal wall section area in a CT image; analyzing and acquiring an abnormal index of each pixel point in each non-intestinal-wall section area; based on the abnormal index and the distribution characteristic of each pixel point, obtaining all focus sub-regions; analyzing and acquiring a focus score of each focus sub-region, and further combining different focus sub-regions to acquire all focus regions; and finally, screening out a to-be-marked focus area from all focus areas and marking the to-be-marked focus area. According to the method, by analyzing the characteristics that the texture of the intestinal wall surface and the shape of the intestinal wall cross section are changed due to colon cancer, and further combining the area characteristics and the distribution characteristics of the lesions in different lesion stages, the lesion region is accurately obtained and marked, and the marking effect of the colon cancer lesion is improved.

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

According to the building system for enhancing the large language model based on the knowledge graph, the LLM and the knowledge graph (KG) are combined, the initial response of the model is improved by utilizing verifiable information in the knowledge graph, and therefore factual errors in the reasoning process are remarkably reduced. The KAR framework shows high adaptability, and shows excellent performance in various open-source LLMs (Logistics Language Models). In particular, KAR can promote the discovery of new uses of existing drugs by identifying potential drug-cancer associations, and can assist in predicting drug resistance by analyzing related biomarkers and genetic mechanisms. In order to evaluate knowledge network question and answer tasks in the field of biomedicine, a benchmark test named cross-domain tumor question and answer is developed. The KAR framework significantly improves the accuracy and practicability of the LLM in the field of biomedicine, and shows the excellent performance of the LLM in biomedicine questions and answers.

The present disclosure provides methods and systems for classifying and / or monitoring a cancer of a subject. A method for assessing a cancer of a subject may comprise obtaining a data set comprising image and / or tabular data from the subject and processing the data with one or more trained algorithms to classify the cancer of the subject. The cancer of the subject may be assessed based on the results of the classification.

The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

The present disclosure provides a nucleic acid molecule (e.g., a plasmid or vector) comprising: a nucleic acid sequence encoding a bicistronic or polycistronic LAMP construct comprising a specific fragment of an LAMP endodomain and an antigen domain heterologous to the LAMP protein to provide at least one antigen for eliciting an immune response, wherein the antigen expressed by the construct is optionally processed and presented to a class II MHC molecule; and a nucleic acid sequence encoding an immune response enhancing polypeptide, optionally secreted from a host cell. The nucleic acid molecules can be used, for example, for the treatment of diseases, in particular allergy, infectious diseases, diabetes, hyperproliferative disorders and / or cancer.

The invention belongs to the field of medical chemistry, and particularly discloses a protein tyrosine phosphatase inhibitor, a pharmaceutical composition and application of the protein tyrosine phosphatase inhibitor, and the protein tyrosine phosphatase inhibitor is a compound shown in a general formula (I) or pharmaceutically acceptable salt of the compound. The invention also discloses a method for using the protein tyrosine phosphatase inhibitor to treat cancers, metabolic diseases and other related diseases. # imgabs0 #